^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    212Pb-VMT-𝛼-NET

    i
    Other names: 212Pb-VMT-𝛼-NET, [212Pb]VMT-𝛼-NET alpha-particle therapy, [212Pb]VMT-α-NET
    Associations

    News

    Trials
    Company:
    Perspective Therap
    Drug class:
    α radiation emission, SSTR2 inhibitor
    Related drugs:
    Associations

    News

    Trials
    7d
    A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors (clinicaltrials.gov)
    P1, N=24, Active, not recruiting, David Bushnell | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    212Pb-VMT-𝛼-NET
    5ms
    A Safety Study of 212Pb-VMT-alpha-NET in Patients With Neuroendocrine Tumors (clinicaltrials.gov)
    P1, N=24, Recruiting, David Bushnell
    New P1 trial
    |
    212Pb-VMT-𝛼-NET
    over1year
    212-Pb-VMT: Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Neuroendocrine Tumors (clinicaltrials.gov)
    P1/2, N=52, Not yet recruiting, Viewpoint Molecular Targeting
    New P1/2 trial • Metastases
    |
    SSTR (Somatostatin Receptor) • CD4 (CD4 Molecule) • SSTR2 (Somatostatin Receptor 2)
    |
    SSTR2 expression • SSTR2 positive
    |
    212Pb-VMT-𝛼-NET